Plasma Proteomic Analysis of APOE ϵ4 Homozygotes Identifies Preclinical Alzheimer's Disease Alterations Potentially Treatable with Semaglutide
Dammer, E. B.; Afshar, S.; Bian, S.; The Global Neurodegeneration Proteomics Consortium (GNPC), ; Levey, A. I.; Fortea, J.; Johnson, E. C. B.
Show abstract
Individuals who carry two copies of the apolipoprotein E {varepsilon}4 (APOE{varepsilon}4) allele are at high risk of developing Alzheimers disease (AD), yet the effects of APOE {varepsilon}4 homozygosity on biological pathways related to AD over the lifespan are unknown. Here we analyzed the plasma proteomes of APOE {varepsilon}4/{varepsilon}4 individuals with and without AD-related cognitive impairment (n=413) and compared them to the proteomes of cognitively unimpaired individuals with APOE {varepsilon}3/{varepsilon}3 genotype (n=2764) from ages 20 to 90. Multiple biological pathways were altered in young adulthood in {varepsilon}4 homozygotes including metabolism and glucagon-like peptide 1/insulin growth factor (GLP-1/IGF), mitochondrial, microtubule, proteostasis, and synaptic pathways. Semaglutide--a GLP-1 receptor agonist--demonstrated reversal effects on metabolic and synaptic pathway alterations in {varepsilon}4 homozygotes at preclinical and clinical AD stages. Targeting metabolic and other pathways for therapeutic intervention in {varepsilon}4/{varepsilon}4 individuals by at least age 50 will likely be the most effective approach to decrease risk for AD in this special population.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Interrogating the plasma proteome of repetitive head impact exposure and chronic traumatic encephalopathy 98%
- Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer’s disease 97%
- APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology 95%
Similar papers in this journal
- Peripheral innate immunophenotype in neurodegenerative disease: blood-based profiles and links to survival 95%
- Integrative Brain Transcriptome Analysis Links Complement Component 4 and HSPA2 to the APOE ε2 Protective Effect in Alzheimer Disease 95%
- N1-methylation of adenosine (m1A) in ND5 mRNA leads to complex I dysfunction in Alzheimer's disease 95%
Similar papers in this journal
- TREM2 Risk Variants with Alzheimer’s Disease Differ in Rate of Cognitive Decline 96%
- Entorhinal cortex epigenome-wide association study highlights four novel loci showing differential methylation in Alzheimer's disease 96%
- Increased cerebrospinal fluid and plasma apoE glycosylation is associated with reduced levels of Alzheimer's disease biomarkers 96%
Similar papers in this journal
- A public resource of single cell transcriptomes and multiscale networks from persons with and without Alzheimer's disease 95%
- Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease 95%
- Identification of Chlamydia pneumoniae and NLRP3 inflammasome activation in Alzheimer's disease retina 95%